Want to see PLSE full AI Analyst Report?
PLSE Stock Chart & Stats
$30.23
$2.56(8.47%)
At close: 4:00 PM EDT
$30.23
$2.56(8.47%)
Day’s Range― - ―
52-Week Range$12.56 - $38.29
Previous Close$32.94
Volume432.45K
Average Volume (3M)189.63K
Market Cap
$2.43B
Enterprise Value$1.41K
Total Cash (Recent Filing)$68.32M
Total Debt (Recent Filing)$7.16M
Price to Earnings (P/E)―
Beta1.30
Next Earnings
Aug 06, 2026EPS Estimate
-0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.09
Shares Outstanding69,209,710
10 Day Avg. Volume222,519
30 Day Avg. Volume189,626
Financial Highlights & Ratios
PEG Ratio-0.73
Price to Book (P/B)11.47
Price to Sales (P/S)2643.82
P/FCF Ratio-17.00
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$33.50Price Target Upside10.82% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.14
Revenue Forecast (FY)$2.73M
Bulls Say, Bears Say
Bulls Say
Clinical / Regulatory MomentumSurpassing the enrollment midpoint and accelerating the U.S. IDE materially reduces time-to-market and regulatory execution risk. Completion of a robust pivotal trial supports PMA timing, strengthens clinical credibility, and meaningfully de-risks commercialization and reimbursement discussions over the next 2–6 months.
Procedural Efficiency & Competitive AdvantageSingle‑shot, ultra‑short pulse ablation that shortens procedure and fluoroscopy times is a durable procedural advantage. Lower procedure time, reproducibility and short learning curve can drive faster adoption, higher lab throughput and recurring consumable sales, supporting long‑term commercial economics.
Financing Flexibility And Runway SupportSubstantial cash on hand combined with a large shelf and ATM facility provides optionality to fund pivotal trials and initial commercialization. This structural financing flexibility reduces immediate solvency risk and buys time to generate clinical readouts or revenue inflection that can materially change funding needs.
Bears Say
Sustained Cash BurnVery large and persistent operating cash outflows indicate the business consumes material capital to advance trials and operations. Continued burn requires external financing or rapid commercial scaling, creating dilution risk and constraining strategic optionality if near‑term revenue or milestones lag expectations.
Deep Unprofitability / Negative MarginsNegative gross profit and large net losses show the cost base exceeds current revenue capacity. Until margins structurally improve—via pricing, scale or lower COGS—the firm will struggle to convert clinical wins into sustainable earnings, limiting reinvestment capacity and shareholder value preservation.
Minimal Commercial Revenue BaseRevenue remains tiny relative to operating spend, so commercial traction is immature. Small recurring consumable sales today offer limited capacity to offset clinical and G&A burn, meaning successful transition from trial to scalable adoption is required to justify continued investment and support durable growth.
Pulse Biosciences News
PLSE FAQ
What was Pulse Biosciences’s price range in the past 12 months?
Pulse Biosciences lowest stock price was $12.56 and its highest was $38.29 in the past 12 months.
What is Pulse Biosciences’s market cap?
Pulse Biosciences’s market cap is $2.43B.
When is Pulse Biosciences’s upcoming earnings report date?
Pulse Biosciences’s upcoming earnings report date is Aug 06, 2026 which is in 2 days.
How were Pulse Biosciences’s earnings last quarter?
Pulse Biosciences released its earnings results on May 04, 2026. The company reported -$0.238 earnings per share for the quarter, beating the consensus estimate of -$0.27 by $0.032.
Is Pulse Biosciences overvalued?
According to Wall Street analysts Pulse Biosciences’s price is currently Undervalued.
Does Pulse Biosciences pay dividends?
Pulse Biosciences does not currently pay dividends.
What is Pulse Biosciences’s EPS estimate?
Pulse Biosciences’s EPS estimate is -0.29.
How many shares outstanding does Pulse Biosciences have?
Pulse Biosciences has 69,209,710 shares outstanding.
What happened to Pulse Biosciences’s price movement after its last earnings report?
Pulse Biosciences reported an EPS of -$0.238 in its last earnings report, beating expectations of -$0.27. Following the earnings report the stock price went down -3.841%.
Which hedge fund is a major shareholder of Pulse Biosciences?
Currently, no hedge funds are holding shares in PLSE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pulse Biosciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$33.50 (10.82% Upside)
$33.50 (10.82% Upside)
Blogger Sentiment
Bullish
PLSE Sentiment 80%
Sector Average 65%
Sector Average 65%
Hedge Fund Trend
Increased
By 31.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $13.3M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-15.46%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-38.81%
Trailing 12-Months
Company Description
Pulse Biosciences
Pulse Biosciences, Inc. is an innovative firm specializing in bioelectric medicine. Their primary offering is the CellFX System, a sophisticated, console-based platform that is precisely controlled via software. This system utilizes its proprietary Nano-Pulse Stimulation technology to deliver extremely brief, nanosecond-duration electrical pulses. This advanced method is designed to selectively eliminate target cells without thermal damage, effectively safeguarding adjacent non-cellular tissue. The CellFX System is applied in the treatment of various medical conditions. The company, originally incorporated in 2014 as Electroblate, Inc., officially became Pulse Biosciences, Inc. in December 2015. Its corporate headquarters are situated in Hayward, California.
PLSE Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized substantial clinical progress and clear operational momentum: landmark European feasibility results (strong efficacy and low SAE rate), initiation and acceleration of the U.S. pivotal IDE trial, regulatory milestones and expanded clinical programs (surgical clamp and Vybrance). These positive milestones were balanced against near‑term commercial immaturity (very small product revenue), rising R&D/clinical spend driving wider GAAP and non‑GAAP losses, and a material quarterly cash burn that reduced cash balances. Management has strengthened leadership, prioritized the high‑value catheter program and secured financing flexibility (shelf and ATM) to support execution. On balance, the clinical and operational advances meaningfully outweigh the financial and timing challenges reported.View all PLSE earnings summariesPLSE Stock 12 Month Forecast
Average Price Target
$33.50
▲(10.82% Upside)
Technical Analysis
Ownership Overview
73.02% Insiders
2.26% Mutual Funds
0.33% Other Institutional Investors
21.42% Public Companies and
Individual Investors